A great new study, and with humans too! As the study aptly demonstrates, the primary driver of cocaine cravings is likely stress and the anxiety it causes. This finding is another corroboration of the findings of the great Rat Park experiment/study on “addiction”. In the study below, the administration of both 300mg and 500mg P5 daily, blunted both the anxiety and the cocaine cravings induced by stress, with the 500mg dose completely eliminating both anxiety and cravings. The P5 was administered orally, twice daily at a dose of 150mg and 250mg for the 300mg and the 500mg groups respectively. Perhaps the even more valuable finding was that P5, at the 500mg daily dose, completely blocked the elevated heart rate and systolic/diastolic blood pressure caused by the stress. On a related note, P5 has also been shown to block both the development of tolerance as well as the cravings for other “addictive” substances such as alcohol (animal study) and benzodiazepine drugs (human study). In other words, P5 may have a great potential not only for “addiction”, but also for hypertension and cardiovascular disease (CVD), since elevated blood pressure and stress are the primary causal factors of the latter. Also, considering the lack of side effects in this study, P5 may actually be preferable to the drugs Big Pharma peddles.
“…This is the first study to test the effects of two supraphysiologic doses of pregnenolone in an established and validated model of provoked stress- and cocaine cue-induced craving, anxiety and autonomic arousal in individuals with cocaine use disorder (CUD). The study findings show that exogenous pregnenolone (a) increased circulating levels of pregnenolone, (b) decreased stress- and cue-induced craving, (c) dose-specifically reduced anxiety and (d) decreased autonomic responses at the higher dose but not the lower dose. Moreover, despite the small sample sizes and preliminary nature of the study, the results produced large effect sizes in the range of 0.5 to 1.34 for craving, anxiety, and autonomic measures indicating robust effect of pregnenolone doses. These effects sizes also indicated adequate power ranging from 0.90 to 0.99 with the current sample size for detecting differences between the tested doses of pregnenolone and placebo. The current results support the use of human laboratory models as an experimental therapeutic strategy for early assessment of the effects of target compounds such as pregnenolone for intermediate outcomes of drug craving, anxiety and physiological adaptations associated with CUD. On the basis of these results, current findings support pregnenolone as a promising target to reduce provoked craving, anxiety and autonomic system activation in CUD.”